Chemotherapy-Induced Peripheral Neurotoxicity as A Risk Factor for Poor Sleep Quality in Breast Cancer Survivors Treated with Docetaxel.

Clicks: 259
ID: 264525
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #13 of 50 articles by views in Asia-Pacific journal of oncology nursing

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The purpose of this study was to explore sleep quality and to determine whether chemotherapy-induced peripheral neurotoxicity is a risk factor for poor sleep quality in breast cancer survivors who receive docetaxel treatment.Secondary data analysis from a cross-sectional study. Sample characteristics were collected using an information sheet. Independent variables included the Hospital Anxiety and Depression Scale (HADS), the Patient Neurotoxicity Questionnaire (PNQ), and the Identification Pain Questionnaire (ID pain). Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). We performed descriptive analyses and simple logistic regression.A total of 98 participants were included. More than 60% of them reported poor sleep quality, with their average PSQI score being 7.54 ± 4.45. Poor subjective sleep quality (1.37 ± 0.88) and short sleep duration (1.37 ± 1.08) were their main problems. In addition, significant risk factors for poor sleep quality were chronic illness (odds ratio [OR] = 2.753, = 0.041), anxiety (OR = 7.714, = 0.009), neuropathic pain (OR = 11.261, = 0.022), sensory neuropathy (OR = 2.529, = 0.032), motor neuropathy (OR = 3.781, = 0.002), and undergoing chemotherapy (OR = 2.593, = 0.027). Targeted therapy that some survivors received served as a protective factor (OR = 0.351, = 0.015).We found a high prevalence of poor sleep quality in breast cancer survivors treated with docetaxel. The results indicated that, in addition to clinical characteristics and psychological discomfort, chemotherapy-induced peripheral neurotoxicity is a significant risk factor for poor sleep quality.
Reference Key
chanchemotherapyinducedasiapacific Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Chan, Ya-Ning;Jheng, You-Wun;Wang, Ya-Jung;
Journal Asia-Pacific journal of oncology nursing
Year Year not found
DOI
10.4103/apjon.apjon_51_20
URL
Keywords
Risk factors Breast cancer sleep quality chemotherapy-induced peripheral neurotoxicity

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.